Recent review of pediatric stroke data shows how costly a stroke is for a pediatric VAD patient, as well as demonstrates how a stroke complicates a patient's clinical course and outcome.
Failing Fontan population discussed at March meeting. Action will create a Learning Lab for this specialized patient population.
VAD Program Pathway activity conducted at design meeting to identify strengths and opportunities of participating care centers.
Action network standardized Bivalirudin use in VAD patients.
Learning Labs created to achieve the global aim of reducing the rate of stroke in VAD patients. Learning Lab groups are focused and divided into 3 key areas: Anticoagulation, Communication, and Hypertension.